News25/Ratings3
News · 26 weeks87+6%
2026-04-192026-10-11
Mix5590d
- SEC Filings20(36%)
- Insider15(27%)
- Other14(25%)
- Leadership5(9%)
- Analyst1(2%)
Latest news
25 items- SECSEC Form 6-K filed by Cybin Inc.6-K - Helus Pharma Inc. (0001833141) (Filer)
- PRHelus Pharma Appoints Dr. Suresh Durgam to Board of DirectorsThis news release constitutes a "designated news release" for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Suresh Durgam, M.D., to its Board of Directors. Dr. Durgam previously served on the Company’s Scientific Advisory Board. Dr. Durgam is a CNS drug-development exe
- SECSEC Form 6-K filed by Cybin Inc.6-K - Helus Pharma Inc. (0001833141) (Filer)
- PRHelus Pharma to Host Investor Presentation on October 21, 2026NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce that the Company will host an investor presentation on October 21, 2026. Discussion topics will include HLP003, the Company’s proprietary NSA in Phase 3 development for the adjunctive treatment of major depressive disorder ("MDD"), and HLP004, its proprietary NSA in Phase 2 development for generalized anxiety disorder ("GAD"). The presentation will also include key opinion leaders’ perspectives on the current and e
- SECSEC Form 6-K filed by Cybin Inc.6-K - Helus Pharma Inc. (0001833141) (Filer)
- SECSEC Form 6-K filed by Cybin Inc.6-K - Helus Pharma Inc. (0001833141) (Filer)
- INSIDERDirector So Eric H. L. was granted 248,000 shares, increasing direct ownership by 6% to 4,713,014 units (SEC Form 4)4 - Helus Pharma Inc. (0001833141) (Issuer)
- INSIDERChief Financial Officer Cavers Greg bought $38,730 worth of shares (3,000 units at $12.91) (SEC Form 4)4 - Helus Pharma Inc. (0001833141) (Issuer)
- INSIDERNew insider Cavers Greg claimed ownership of 125,937 shares (SEC Form 3)3 - Helus Pharma Inc. (0001833141) (Issuer)
- INSIDERChief Growth Officer Glavine Paul was granted 248,000 shares, increasing direct ownership by 6% to 4,750,191 units (SEC Form 4)4 - Helus Pharma Inc. (0001833141) (Issuer)
- SECSEC Form 6-K filed by Cybin Inc.6-K - Helus Pharma Inc. (0001833141) (Filer)
- PRHelus Pharma Announces Completion of Legal Name ChangeNEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce the Company’s legal name has been changed from "Cybin Inc." to "Helus Pharma Inc." effective October 1, 2026. The name change was approved by shareholders at the Company’s annual and special meeting of shareholders held on September 22, 2026. The name change follows the Company’s adoption of the business name "Helus Pharma" on January 5, 2026 and reflects the Company’s anticipated transformation from a clinical stage dis
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- PRHelus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name ChangeTORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the "Meeting"). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Mee
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- PRHelus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry SummitNEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually September 23, 2026. The fireside chat will be webcast live on Wednesday, September 23, 2026 at 9:00 a.m. EDT. To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma’
- INSIDERChief Executive Officer Halstead Michael bought $1,347,050 worth of shares (100,000 units at $13.47), increasing direct ownership by 146% to 168,568 units (SEC Form 4)4 - CYBIN INC. (0001833141) (Issuer)
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- PRHelus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatmentfor major depressive disorder ("MDD") NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026, September 15–19, 2026, at the Ernest N. Morial Conven
- INSIDERNew insider Halstead Michael claimed ownership of 68,568 shares (SEC Form 3)3 - CYBIN INC. (0001833141) (Issuer)
- INSIDERChief Growth Officer Glavine Paul bought $1,247,190 worth of shares (100,000 units at $12.47), increasing direct ownership by 2% to 4,271,252 units (SEC Form 4)4 - CYBIN INC. (0001833141) (Issuer)
- INSIDERChief Growth Officer Glavine Paul bought $1,247,190 worth of shares (100,000 units at $12.47), increasing direct ownership by 2% to 4,271,252 units (SEC Form 4)4 - CYBIN INC. (0001833141) (Issuer)
- INSIDERExecutive Chair So Eric H. L. bought $1,238,670 worth of shares (100,000 units at $12.39), increasing direct ownership by 2% to 4,465,014 units (SEC Form 4)4 - CYBIN INC. (0001833141) (Issuer)
- SECSEC Form 6-K filed by Cybin Inc.6-K - CYBIN INC. (0001833141) (Filer)
- PRHelus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New YorkNEW YORK and TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The fireside chat will be webcast live on Wednesday, September 16, 2026 at 8:30 a.m. EDT. To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma’s investor relations website. A
HELP FAQ
5 questionsWhere does HELP stock trade?
Cybin Inc. (HELP) is listed on NASDAQ.What sector and industry is HELP in?
Cybin Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about HELP?
Cybin Inc. has had 3 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $1600.00 price target on 2026-07-27. Recent price targets range from $800.00 to $2200.00.What companies are similar to HELP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare HELP side-by-side with any of them on Quantisnow.How can I track HELP on Quantisnow?
Quantisnow aggregates Cybin Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HELP to receive live email and push alerts on every new disclosure.